Cinfa: Improving the quality of healthcare solutions for patients

Cinfa is a Spanish pharmaceutical laboratory with 55 years of experience and more than 2,200 professionals. Their main objective is to provide top-notch health solutions through accessible and high-quality products, which has earned them a prominent place in the national and international pharmaceutical market. In 2023, Cinfa’s turnover reached 760 million dollars.

European excellence with global impact

As a 100% Spanish-owned enterprise, Cinfa is dedicated to improving healthcare accessibility with the highest quality standards. In its home country, it dominates the pharmaceutical market, leading both in terms of product value and the number of treatments dispensed in retail pharmacies.

Cinfa’s mission extends far beyond Spain’s boarders. With a presence in more than 100 countries, it works to ensure that its healthcare solutions are accessible to people around the world.

Innovation at the center

In addition, the laboratory is committed to innovation, it has an R+D team with more than 100 people dedicated to the development of advanced solutions for healthcare.

Over the past decade, it has invested a total of $480 million in research and development and collaborates with more than 70 universities and research centers around the world, fostering an environment of continuous improvement and advancement.

Various product categories and quality assurance

It has a wide range of products, including prescription medicines, consumer health care (HCC) solutions, mobility and personal care products. This diversity allows it to meet a wide range of healthcare needs, further solidifying its position as a trusted partner in healthcare. Always operating under the strict regulatory frameworks of bodies such as the FDA and the European Medicines Agency, thus guaranteeing that its products consistently meet the highest quality standards.

Global reach with a regional focus

Cinfa’s global presence extends to regions such as the Middle East, Central America and Southeast Asia. In the Middle East, Cinfa has made a significant impact, collaborating with more than 8,500 medical centers and pharmacies in Saudi Arabia, Qatar, the United Arab Emirates and Kuwait.

Mikel Zumalabe, International Marketing Manager at Cinfa Group, has highlighted that “10 years ago, Cinfa started its activity in the region initially focusing on the United Arab Emirates market. Later it has expanded its reach to other countries such as KSA, Qat and KWT with the intention of continuing to expand”.

Its international spokesperson has added that, “Cinfa’s main goal is to expand to new countries in the region, such as Bahrain, and to launch new and innovative molecules within the Anatomical Therapeutic Chemical (ATC) classification system in which it is present today, as well as to venture into new ATCs that have a great impact on the region, such as diabetes.”

Cardiology is one of the main therapeutic areas in the Middle East

Cinfa has a wide range of products in the cardiovascular therapeutic area that cover several diseases such as hypercholesterolemia, hypertension or heart failure, as well as their role in the prevention of cardiovascular diseases.

As its medical spokesperson, Dr. Alicia López de Ocáriz, has highlighted, “Cinfa continues to develop medicines in this area, for example, for heart failure. Everything we can do to improve the heart function of these patients will improve their quality of life and reduce the number of hospitalizations that represent the greatest expense associated with this disease”.

Currently, Cinfa’s research and development team is also focused on anticoagulant medicines. Specifically, it is working on two types, more effective and safer: direct thrombin inhibitors (DTIs) and direct factor Xa inhibitors.

In terms of where cardiology should continue to advance, Dr. Alicia López de Ocáriz has highlighted that “there is currently a need to improve current therapies, which are largely palliative therapies, to also address massive tissue destruction after myocardial infarction. To this end, we need to continue to work on strengthening the efforts dedicated to myocardial regeneration”.